Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Neuropsychological Function in Children with ADHD
NCT00216918Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Neuropsychological Status (NEPSY) at 6 months. Started Sep 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00216918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216918.